Patents by Inventor Felix Oden

Felix Oden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized antibodies against CD269 (BCMA)
    Patent number: 11820829
    Abstract: A nucleic acid molecule encoding an antibody or antibody fragment, wherein the antibody or antibody fragment binds an epitope of the extracellular domain of CD269 (BCMA), a host cell comprising the nucleic acid molecule and a composition comprising the host cell.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: November 21, 2023
    Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
    Inventors: Felix Oden, Stephen Marino, Oliver Daumke
  • Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
    Patent number: 11667722
    Abstract: A composition comprising a cell or a population thereof, wherein the cell comprises a polynucleotide encoding an antibody or a fragment thereof that binds CD269 (BCMA), wherein the binding to CD269 (BCMA) disrupts the interaction between CD269 and its native ligands (BAFF and APRIL). Also disclosed is treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: June 6, 2023
    Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
    Inventors: Martin Lipp, Felix Oden, Uta Höpken, Gerd Müller, Oliver Daumke, Stephen Marino, Daniel Olal
  • Gamma-carboline compounds for the detection of Tau aggregates
    Patent number: 11306089
    Abstract: The present invention relates to novel compounds of the formula (II) and formula (III) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: April 19, 2022
    Assignee: LIFE MOLECULAR IMAGING LIMITED
    Inventors: Mathias Berndt, Andre Müller, Felix Oden, Hanno Schieferstein, Heribert Schmitt-Willich, Heiko Kroth, Jérôme Molette
  • HUMANIZED ANTIBODIES AGAINST CD269 (BCMA)
    Publication number: 20210079108
    Abstract: A nucleic acid molecule encoding an antibody or antibody fragment, wherein the antibody or antibody fragment binds an epitope of the extracellular domain of CD269 (BCMA), a host cell comprising the nucleic acid molecule and a composition comprising the host cell.
    Type: Application
    Filed: October 23, 2020
    Publication date: March 18, 2021
    Inventors: Felix Oden, Stephen Marino, Oliver Daumke
  • GAMMA-CARBOLINE COMPOUNDS FOR THE DETECTION OF TAU AGGREGATES
    Publication number: 20210047321
    Abstract: The present invention relates to novel compounds of the formula (II) and formula (III) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Application
    Filed: January 22, 2019
    Publication date: February 18, 2021
    Inventors: Mathias BERNDT, Andre MÜLLER, Felix ODEN, Hanno SCHIEFERSTEIN, Heribert SCHMITT-WILLICH, Heiko KROTH, Jérôme MOLETTE
  • AZACARBOLINE COMPOUNDS FOR THE DETECTION OF TAU AGGREGATES
    Publication number: 20210041447
    Abstract: The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging. The present invention also discloses intermediates which are useful in the preparation of these compounds.
    Type: Application
    Filed: January 22, 2019
    Publication date: February 11, 2021
    Inventors: Mathias BERNDT, Andre MÜLLER, Felix ODEN, Hanno SCHIEFERSTEIN, Heribert SCHMITT-WILLICH, Heiko KROTH, Jérôme MOLETTE, Emanuele GABELLIERI, Cédric BOUDOU
  • Compounds for imaging Tau protein aggregates
    Patent number: 10865207
    Abstract: The present invention relates to novel compounds of the formula (I) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: December 15, 2020
    Assignees: AC IMMUNE S.A., LIFE MOLECULAR IMAGING SA
    Inventors: Heiko Kroth, Jérôme Molette, Hanno Schieferstein, Andre Müller, Heribert Schmitt-Willich, Mathias Berndt, Felix Oden
  • Humanized antibodies against CD269 (BCMA)
    Patent number: 10851172
    Abstract: A method of treating a medical disorder associated with the presence of pathogenic B cells expressing B cell maturation antigen (BCMA), the method comprising administering to a subject an isolated antibody or antibody fragment comprising specific VH and VL domain complementary determining region (CDR) sequences, wherein the antibody or fragment thereof specifically binds an epitope of the extracellular domain of CD269 (BCMA).
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: December 1, 2020
    Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT
    Inventors: Felix Oden, Stephen Marino, Oliver Daumke
  • ANTIBODY THAT BINDS CD269 (BCMA) SUITABLE FOR USE IN THE TREATMENT OF PLASMA CELL DISEASES SUCH AS MULTIPLE MYELOMA AND AUTOIMMUNE DISEASES
    Publication number: 20200369778
    Abstract: A composition comprising a cell or a population thereof, wherein the cell comprises a polynucleotide encoding an antibody or a fragment thereof that binds CD269 (BCMA), wherein the binding to CD269 (BCMA) disrupts the interaction between CD269 and its native ligands (BAFF and APRIL). Also disclosed is treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
    Type: Application
    Filed: July 8, 2020
    Publication date: November 26, 2020
    Inventors: Martin LIPP, Felix ODEN, Uta HÖPKEN, Gerd MÜLLER, Oliver DAUMKE, Stephen MARINO, Daniel OLAL
  • Compounds for imaging Tau protein aggregates
    Patent number: 10835624
    Abstract: The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: November 17, 2020
    Assignees: AC IMMUNE S.A., LIFE MOLECULAR IMAGING SA
    Inventors: Heiko Kroth, Jérôme Molette, Vincent Darmency, Hanno Schieferstein, Andre Müller, Heribert Schmitt-Willich, Mathias Berndt, Felix Oden, Emanuele Gabellieri
  • Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
    Patent number: 10745486
    Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 18, 2020
    Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
    Inventors: Martin Lipp, Felix Oden, Uta Höpken, Gerd Müller, Oliver Daumke, Stephen Marino, Daniel Olal
  • COMPOUNDS FOR IMAGING TAU PROTEIN AGGREGATES
    Publication number: 20190263817
    Abstract: The present invention relates to novel compounds of the formula (I) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Application
    Filed: July 21, 2017
    Publication date: August 29, 2019
    Inventors: Heiko KROTH, Jerome MOLETTE, Hanno SCHIEFERSTEIN, Andre MULLER, Heribert SCHMITT-WILLICH, Mathias BERNDT, Felix ODEN
  • COMPOUNDS FOR IMAGING TAU PROTEIN AGGREGATES
    Publication number: 20190262480
    Abstract: The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Application
    Filed: July 21, 2017
    Publication date: August 29, 2019
    Inventors: Heiko KROTH, Jérôme MOLETTE, Vicent DARMENCY, Hanno SCHIEFERSTEIN, Andre MÜLLER, Heribert SCHMITT-WILLICH, Mathias BERNDT, Felix ODEN, Emanuele GABELLIERI
  • HUMANIZED ANTIBODIES AGAINST CD269 (BCMA)
    Publication number: 20190112382
    Abstract: A method of treating a medical disorder associated with the presence of pathogenic B cells expressing B cell maturation antigen (BCMA), the method comprising administering to a subject an isolated antibody or antibody fragment comprising specific VH and VL domain complementary determining region (CDR) sequences, wherein the antibody or fragment thereof specifically binds an epitope of the extracellular domain of CD269 (BCMA)
    Type: Application
    Filed: October 25, 2018
    Publication date: April 18, 2019
    Inventors: Felix Oden, Stephen Marino, Oliver Daumke
  • ANTIBODY THAT BINDS CD269 (BCMA) SUITABLE FOR USE IN THE TREATMENT OF PLASMA CELL DISEASES SUCH AS MULTIPLE MYELOMA AND AUTOIMMUNE DISEASES
    Publication number: 20190106499
    Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 11, 2019
    Inventors: Martin Lipp, Felix Oden, Uta Höpken, Gerd Müller, Oliver Daumke, Stephen Marino, Daniel Olal
  • Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
    Patent number: 10189906
    Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: January 29, 2019
    Assignee: MAX-DELRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
    Inventors: Martin Lipp, Felix Oden, Uta Höpken, Gerd Müller, Oliver Daumke, Stephen Marino, Daniel Olal
  • Humanized antibodies against CD269 (BCMA)
    Patent number: 10144782
    Abstract: The invention relates to humanized antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: December 4, 2018
    Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT
    Inventors: Felix Oden, Stephen Marino, Oliver Daumke
  • HUMANIZED ANTIBODIES AGAINST CD269 (BCMA
    Publication number: 20170166649
    Abstract: The invention relates to humanized antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
    Type: Application
    Filed: April 30, 2015
    Publication date: June 15, 2017
    Applicant: MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT
    Inventors: Felix Oden, Stephen Marino, Oliver Daumke
  • ANTIBODY THAT BINDS CD269 (BCMA) SUITABLE FOR USE IN THE TREATMENT OF PLASMA CELL DISEASES SUCH AS MULTIPLE MYELOMA AND AUTOIMMUNE DISEASES
    Publication number: 20150284467
    Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
    Type: Application
    Filed: November 1, 2013
    Publication date: October 8, 2015
    Inventors: Martin Lipp, Felix Oden, Uta Höpken, Gerd Müller, Oliver Daumke, Stephen Marino, Daniel Olal